BHCM
KNSA icon

Brevan Howard Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Brevan Howard Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
4,958
-48,924
-91% -$2.54M ﹤0.01% 1684
2026
Q1 		$2.59M Buy
+53,882
New +$2.39M 0.02% 460
2024
Q2 		– Sell
-59,954
Closed -$1.18M – 1232
2024
Q1 		$1.18M Buy
+59,954
New +$1.17M 0.01% 226

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Brevan Howard Capital Management's KNSA Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 91% in Q2 2026, selling an estimated $2.54M and leaving 4,958 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #1684.

Brevan Howard Capital Management first reported a position in KNSA in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.59M in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Brevan Howard Capital Management held 4,958 shares of Kiniksa Pharmaceuticals worth $317K as of Q2 2026.
  • Brevan Howard Capital Management sold 48,924 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.54M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1684 holding.
  • Brevan Howard Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Kiniksa Pharmaceuticals position peaked at $2.59M in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.